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(57) ABSTRACT 
The present invention provides, inter alia, a PC12 cell 
quiescently infected With a neurotropic virus. Preferred 
quiescently-infected neural cells are those Wherein the neu 
rotropic virus is a neurotropic herpes virus. Methods related 
to these and other materials are also provided. 
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NEURONAL CELL MODEL AND METHODS 
OF USE THEREFOR 
This application claims priority to US. Provisional 
Patent Application No. 60/078,850, ?led Mar. 20, 1998. 
This Work Was supported by NIH grant number NIH 
(NIDR) R29 DE11104; the government may have certain 
rights in this invention. 
FIELD OF THE INVENTION 
In this disclosure, it is demonstrated that neurally 
differentiated cells can be infected With viruses in a manner 
that supports a long-term non-productive infection. This 
model When compared to others is unique in that 1) quies 
cent infection is established in a neuronal cell line that has 
features reminiscent of ganglionic neurons, 2) an inhibitor of 
DNA synthesis is needed only to establish the quiescent 
state, not maintain it, 3) an inhibitor of viral gene expression 
is not required to establish the quiescent state, 4) the 
non-productive state is reversible With spontaneous and 
inducible reactivation, and 5) quiescence is long term. 
In particular, neuronally differentiated PC12 cells, estab 
lished from pheochromocytoma of rat adrenal medulla, are 
used to host a persistent viral infection. First, cells are 
differentiated by groWing cells in de?ned medium contain 
ing nerve groWth factor. Under these conditions cells extend 
neurites, develop electrical excitability and express genes 
encoding neuronal cell-speci?c proteins (Green and Tischler 
1976; Green and Tischler 1982). Cells are maintained in 
serum-free medium to render them nondividing. Next, cells 
are inoculated With neurotropic virus (eg., human herpes 
virus) under conditions that restrict viral propagation. A 
de?ned regimen of media changes are used to establish a 
quiescent and nonproductive state folloWing the WithdraWal 
of the antiviral treatment. Evidence of establishment of a 
quiescent and persistent infection comes from assays dem 
onstrating that cells survive the infection, a nonproductive 
viral state is established in the majority of cultures, and cells 
support spontaneous and inducible virus production. 
BACKGROUND OF THE INVENTION 
The lack of a universally accepted neural cell-line that 
supports viral latency, in particular, HSV-1 latency, has 
restricted the understanding of the molecular events 
involved in reactivation from latency. As a result, animals 
and tissue culture have served to provide an understanding 
of the mechanisms of this event. Animal models, hoWever, 
are limited by dif?culties. These include: latency and 
reactivation events that are in?uenced by viral strains With 
different primary groWth phenotypes, (ii) the limited number 
of neurons latently infected in animal models (Bloom et al, 
1996; Hill et al, 1996; Maggioncalda et al, 1996; Mehta et 
al, 1995; Ramakrishnan 1994; SaWtell, 1997; SaWtell et al, 
1998; Thompson and SaWtell, 1997), and (iii) inaccurate 
quantitation of reactivation events When measuring virus 
production at the recurrent site as a result of in?uences of 
transport, replication in epithelium, and the immune 
response. 
A major advantage of tissue and cell culture models 
includes the ability to observe virus at the single cell level 
Without the overlay of immunological events that modulate 
the eventual appearance of virus in the host. Tissue culture 
models derived from neuronal and sympathetic ganglia have 
properties of the in vivo system including: restricted 
transcription of the HSV genome (Doerig et al, 1991; 
Halford et al, 1996; Smith et al, 1992; Smith et al, 1994), (ii) 
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lack of virus production folloWing removal of the inhibitory 
agent, (Wilcox and Johnson, 1988) (iii) the presence of 
latency-associated transcripts (LATs) (Doerig et al, 1991; 
Smith et al, 1994), (iv) impaired reactivation of thymidine 
kinase negative virus (Wilcox et al, 1992), and (v) inducible 
reactivation (Halford et al, 1996; Moriya et al, 1994; Smith 
et al, 1992; Wilcox and Johnson, 1988; Wilcox and Johnson 
1987; Wilcox et al, 1990). Nevertheless, preparation of 
dissected ganglia is inconvenient, material is limited, animal 
use is required, and axotomy introduces traumatic factors 
that in?uence reactivation of virus. 
For the above reasons, cell culture models are important 
for studying the molecular details of the establishment, 
maintenance and reactivation stages of latency. Cell culture 
also alloWs for an unlimited supply of a de?ned host cell and 
the ability to manipulate genetic material. Over the past 25 
years, cell culture systems using ?broblast cultures (Harris 
and Preston, 1991; Jamieson et al, 1995; O’Neill, 1977; 
O’Neill et al, 1972; Russell et al, 1987; Scheck et al, 1989; 
Wigdahl et al, 1982a; Wigdahl et al, 1982b; Wigdahl et al, 
1983) and lymphocytes (Hammer et al, 1981; Youssou?an et 
al, 1982) have enabled the study of HSV-1 during a latent 
like state. 
These models, hoWever required loW input multiplicities 
and/or the use of replication inhibitors such as anti-viral 
agents, inhibitory temperatures, or the use of a mutant virus, 
to prevent virus production. A cell line that has neural 
morphology and physiology, can survive infection and per 
mit viral production, alloW establishment of a long term 
nonproductive viral infection, and support virus in a state 
suitable for reactivation studies Would be more desirable. 
The rat pheochromocytoma (PC12) cell line (used in the 
present model) is of neural crest origin and can be morpho 
logically differentiated With the addition of nerve groWth 
factor (Greene and Tischler, 1976). These cells have been 
shoWn to be permissive to HSV-1 infection (Bloom and 
Stevens, 1994; Rodahl and Haar, 1997; Rubenstein and 
Price, 1983a; Rubenstein and Price 1983b, Rubenstein and 
Price, 1984), and have been used to examine HSV-1 gene 
regulation and expression (Frazier et al, 1996a; Frazier et al, 
1996b; Jordan et al, 1998; Leib et al, 1991; Xie et al, 1996) 
and the function of HSV origins of DNA replication 
(HardWicke and Schaffer, 1997). The relevance of these 
studies, hoWever remains incomplete since the ability of 
these cells to harbor HSV-1 in a “latent-like” state has not 
been demonstrated (Block et al, 1994). Block also differs 
from the present invention in that Block asserted that 
WithdraWal of NGF from a serum-containing medium 
resulted in reactivation, implying that NGF and serum Were 
necessary in any such model. 
Previous studies have demonstrated NGF-differentiated 
PC12 (Nd-PC12) cells can be maintained as non-dividing 
cultures both in the presence and absence of serum (Greene, 
1978; Greene and Tischler, 1976). These cultures have been 
studied on non-coated (Block et al, 1994) and collagen 
coated dishes (Greene and Tischler, 1976). Other studies 
indicate that a signi?cant portion of PC12 cells cultured in 
the presence of serum continue to divide (Goodman et al, 
1979; Ignatius et al, 1985). 
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SUMMARY OF THE INVENTION 
The present invention provides, inter alia, neural cells 
comprising a PC12 cell quiescently infected With a neuro 
tropic virus. Preferred quiescently-infected neural cells are 
those Wherein the neurotropic virus is a neurotropic herpes 
virus. More preferred are quiescently-infected neural cells 
Wherein the neurotropic virus is a neurotropic human herpes 
virus. More preferred are quiescently-infected neural cells 
Wherein the neurotropic herpes virus is a human herpes 
simplex 1 virus. HoWever, those quiescently-infected neural 
cells Wherein the neurotropic virus is selected from the 
group consisting essentially of varicella zoster viruses, 
polyoma viruses, measles viruses, human immunode?ciency 
viruses, papillomaviruses, adenoviruses, cytomegaloviruses, 
epstein barr viruses, hepatitis viruses, coronaviruses, cox 
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses, 
togaviruses, and rhinoviruses, are also preferred. 
Also provided are methods of establishing quiescently 
infected neural cells, comprising introducing a neurotropic 
virus to neurally-differentiated and viable PC12 cells in a 
serum-free medium, said differentiated PC12 cells being in 
a container; and incubating said container With an antiviral 
reagent for a time necessary to accomplish quiescence of 
viral activity; and removing said antiviral agent from said 
container. Preferred such methods are those Wherein the 
neurotropic virus is a neurotropic herpes virus. More pre 
ferred are those methods Wherein the neurotropic herpes 
virus is a human herpes simplex 1 virus. HoWever, those 
methods Wherein the neurotropic virus is selected from the 
group consisting essentially of varicella zoster viruses, 
polyoma viruses, measles viruses, human immunode?ciency 
viruses, papillomaviruses, adenoviruses, cytomegaloviruses, 
epstein barr viruses, hepatitis viruses, coronaviruses, cox 
sackie viruses, rabies viruses, flaviviruses, paramyxoviruses, 
togaviruses, and rhinoviruses are also preferred. Methods 
Wherein the neurotropic herpes virus is a human herpes 
simplex 1 virus and the antiviral agent is acyclovir are 
preferred, especially methods Wherein said container is 
incubated With an antiviral composition for approximately 5 
to 12 days, more especially methods Wherein said container 
is incubated at a temperature less than 40 degrees Celsius, 
and most especially Wherein said serum free medium alloWs 
for constant cell density and imparts neural characteristics to 
said cells. 
Also provided are methods of reactivating a quiescent 
virus from neural cell, comprising: introducing a reactivator 
to a quiescendy-infected neural cell described herein. 
Also provided are methods for determining the ability of 
a test reagent to suppress virus reactivation from a 
quiescently-infected neural cell, comprising introducing a 
test reagent to a quiescently-infected neural cell described 
herein; and introducing to said neural cell a reactivator; and 
determining if reactivation has been suppressed. 
Also provided are methods for determining the ability of 
a test reagent to induce virus reactivation from in a neural 
cell, comprising introducing a test reagent to a quiescently 
infected neural cell described herein; and determining if 
reactivation has been induced. 
Also provided are methods for eliciting phenotypic 
change in a neural cell, introducing a reactivator to a 
quiescently-infected neural cell described herein, and elic 
iting a phenotypic change in said neural cell. Preferred are 
such methods Wherein said phenotypic change is selected 
from the group consisting of synthesis of myelin, synthesis 
of neurotransmitter, cell death, and viral shedding. 
Also provided are methods for determining the suscepti 
bility of a person infected With a quiescent virus to reacti 
US 6,268,124 B1 
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vation by a reagent, comprising introducing a reactivator to 
a quiescently-infected neural cell described herein, Wherein 
the neurotropic virus is a strain isolated from a person 
infected With said neurotropic virus; and determining the 
relative magnitude of phenotypic or genomic reactivation. 
Also provided are methods to determine the ability of a 
non-neurotropic virus to become quiescent and/or reactivat 
able in a neural cell line, comprising introducing a non 
neurotropic virus to differentiated and viable PC12 cells in 
a serum-free medium, said differentiated PC12 cells being in 
a container; and incubating said container With an antiviral 
reagent for a time necessary to accomplish quiescence of 
viral activity; and removing said antiviral agent from said 
container; and determining said non-neurotropic virus’s 
ability to become quiescent and or reactivatable. 
Also provided are methods to identify nucleic acid mol 
ecules and/or proteins involved in virus reactivation, com 
prising reactivating a quiescently-infected neural cell 
described herein With a reactivator; and identifying nucleic 
acid molecules and/or proteins Which are uniquely expressed 
during reactivation. 
Also provided are methods to identify the origins of DNA 
replication important to virus reactivation, comprising reac 
tivating a quiescently-infected neural cell described herein 
With a reactivator; and identifying the origins of replication 
Which are uniquely associated With reactivation. 
Also provided are methods to determine a reagent’s 
ability to inhibit establishment of a quiescent viral infection, 
comprising introducing a non-neurotropic virus to differen 
tiated and viable PC12 cells in a serum-free, test reagent 
containing medium, said differentiated PC12 cells being in 
a container; and incubating said container With an antiviral 
reagent for a time necessary to accomplish quiescence of 
viral activity in the absence of said test reagent; and remov 
ing said antiviral agent from said container; and determining 
said test reagent’s ability to inhibit quiescence. 
Also provided are methods to screen an attenuated virus’ 
relative ability to be reactivated, comprising introducing a 
reactivator to a quiescently-infected neural cell described 
herein, Wherein the neurotropic virus is an attenuated virus; 
and determining the relative magnitude of reactivation. 
For the purposes of the present application, the folloWing 
terms shall have the folloWing meanings: 
“a” or “an”, When describing a noun, refers to one or more 
of that noun. 
“antiviral reagent” means a reagent Which prevents viral 
groWth or DNA replication in a cell. 
“composition” means any compound or composition made 
by any means. “Composition” includes synthetic or 
naturally-occurring compounds or compositions, Whether 
puri?ed or not, and can include: biologicals, chemicals, 
herbal extract(s); precursor(s); metabolite(s); and 
ingredient(s), including enantiomer(s) of a racemic mix 
ture. The de?nition of “composition” includes compounds 
produced in situ by virtue of an immune response (ie. 
immunoglobulins and compounds involved in 
in?ammation), as Well as organisms, such as: viruses, 
bacteria and fungi. 
“isolated” means physically removed from a form found in 
nature. For instance, Whole cells, a crude cell extract, 
puri?ed virus, molecularly engineered virus, or arti?cial 
virus Would be “isolated” virus. 
“neurotropic virus” means any virus Which is capable of 
infecting neurons, including viruses Which only tran 
siently infect neurons. 
“quiescent” or “quiescence” means the absence of detectable 
infectious particles in the media and Within the cells, no 
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detectable gene products, no detectable viral gene 
transcription, except for latency associated transcripts. 
“reactivator” means a reagent Which Will cause reactivation 
of quiescent virus. 
“reactivation” means any change in phenotype or genotype 
from a quiescent state. 
“reagent” means a composition or an environmental 
condition, temperature, ultraviolet radiation, etc. 
“virus” means the de?nition as understood by those in the 
art, as Well as viroid particles such as prions, and includ 
ing natural and arti?cial alterations thereof (eg. mutations 
(eg. temperature sensitive mutations), including deletions, 
insertions, etc.) 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 shoWs the groWth characteristics of long-term 
cultures of NGF differentiated PC12 cells. 
FIG. 2 shoWs induced HSV-l production from quiescent 
infected PC12 cell cultures. 
FIG. 3 shoWs induction of HSV-1 from long term 
quiescently-infected PC12 cells. 
FIG. 4 shoWs Southern analysis of HSV-1 transcripts 
produced during the establishment and maintenance of the 
quiescent phase of infection. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides, inter alia, neural cells 
comprising a PC12 cell quiescently infected With a neuro 
tropic virus. Preferred quiescently-infected neural cells are 
those Wherein the neurotropic virus is a neurotropic herpes 
virus. More preferred are quiescently-infected neural cells 
Wherein the neurotropic virus is a neurotropic human herpes 
virus. More preferred are quiescently-infected neural cells 
Wherein the neurotropic herpes virus is a human herpes 
simplex 1 virus. HoWever, those quiescently-infected neural 
cells Wherein the neurotropic virus is selected from the 
group consisting essentially of varicella Zoster viruses, 
polyoma viruses, measles viruses, human immunode?ciency 
viruses, papillomaviruses, adenoviruses, cytomegaloviruses, 
epstein barr viruses, hepatitis viruses, coronaviruses, cox 
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses, 
togaviruses, and rhinoviruses, are also preferred. 
Certain PC12 cells are available commercially as 
described in the examples. PC12 cell variants are Within the 
scope of the present invention, as are any cells derived from 
the neural crest. These materials can be commercially 
obtained from American Type Culture Collection (ATCC, 
Rockville, Md.) or other commercial entities. These cells are 
Within the scope of the present invention as Well. 
Within the meaning of each of the viruses listed in the 
claims are several hundreds of “strains” of those viruses. For 
instance, human herpes virus 1, human herpes virus 6, 
human herpes virus 7, and human herpes viruses 8 are 
“strains” of human herpes virus. The strains of each virus 
type is, of course, included Within the scope of the present 
invention. For instance, human herpes simplex virus 1 
includes the strains listed in the examples, as Well as these 
other strains, such as 17+, KOS, McKrae, Macroplaque, 
Patton, and F. 
Viruses can be obtained by purchasing them commer 
cially (as part of a cell line or tissue sample) from ATCC or 
by obtaining them according to the procedures Well knoWn 
in the art, such as by obtaining clinical isolates, or cultures 
from researches in the ?eld. Textbooks Which discuss 
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manipulations of viruses are many, including: Fields & 
Knipe, Fundamental Virology; Luria et al, General Virology; 
and Fenner et al., Molecular Virology. The present 
quiescently-infected neural cells can be made by the meth 
ods disclosed herein. 
Particularly useful in the preparation of the neural cells 
are the examples, although variations as described herein 
Will also produce the present materials. Moreover, certain 
reasonable optimiZation of the methods can be accomplished 
according to methods Well-known in the art. 
Also provided are methods of establishing quiescently 
infected neural cells, comprising introducing a neurotropic 
virus to neurally-differentiated and viable PC12 cells in a 
serum-free medium, said differentiated PC12 cells being in 
a container; and incubating said container With an antiviral 
reagent for a time necessary to accomplish quiescence of 
viral activity; and removing said antiviral agent from said 
container. Preferred such methods are those Wherein the 
neurotropic virus is a neurotropic herpes virus. More pre 
ferred are those methods Wherein the neurotropic herpes 
virus is a human herpes simplex 1 virus. HoWever, those 
methods Wherein the neurotropic virus is selected from the 
group consisting essentially of varicella Zoster viruses, 
polyoma viruses, measles viruses, human immunode?ciency 
viruses, papillomaviruses, adenoviruses, cytomegaloviruses, 
epstein barr viruses, hepatitis viruses, coronaviruses, cox 
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses, 
togaviruses, and rhinoviruses are also preferred. Methods 
Wherein the neurotropic herpes virus is a human herpes 
simplex 1 virus and the antiviral agent is acyclovir are 
preferred, especially methods Wherein said container is 
incubated With an antiviral composition for approximately 5 
to 12 days, more especially methods Wherein said container 
is incubated at a temperature less than 40 degrees Celsius, 
and most especially Wherein said serum free medium alloWs 
for constant cell density and imparts neural characteristics to 
said cells. 
The methods described herein may utiliZe the speci?c 
conditions described in the examples, but may also vary 
therefrom. Variations include the use of collagen in the 
plating technique; collagen need not be used, but ef?ciency 
Will be improved if it is. Moreover, the plates need not be as 
con?ning as described in the examples; other surfaces, 
including different shapes and siZes, can be used, so long as 
a viable cell culture can be maintained for the length of time 
desired. The multiplicity of infection may be from 0.5 to 
greater than 15, although it the examples describe preferred 
multiplicities for HSV-1 When high reactivation rates are 
desired. HoWever, in certain instances, it may be optimal to 
have loW reactivation rates, depending on the particular use 
of the neural cells. In that case, loWer multiplicities Would be 
optimal. The antiviral reagent used can be any Which causes 
quiescence of the neurotrophic virus. The exempli?ed 
reagent, acyclovir, may be optimiZed chemically for this 
purpose, or other antivirals may be used. For example, AZT, 
lamidudine (3TC) indovir (IDV), gancyclovir, fancyclovir, 
foscamite, idoxyuridine, phosphoacetic acid, 5-?uorouracil, 
or similar compounds and analogs thereof may be used. The 
concentrations of the compound used to cause quiescence 
can also be modi?ed as necessary. Moreover, a combination 
(eg. tWo or more) of antiviral drugs may be used. Incubation 
of the PC12 cells With the antiviral is optimally that 
described in the examples, but can be more or less, depend 
ing on the particular reagent used. OptimiZation of the 
incubation schedule is Within the skill of the art. Lastly, the 
media used can be any that alloWs viable cell groWth, so long 
as it alloWs for constant cell density and may be supple 
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mented reagent or virus in order to transiently inhibits viral 
groWth. It is optimal to change the media as described in the 
examples, but it is not necessary, so long as the cells are 
acceptably viable. 
Also provided are methods of reactivating a quiescent 
virus from neural cell, comprising: introducing a reactivator 
to a quiescently-infected neural cell described herein. 
This aspect of the invention is particularly useful in 
studying reactivation, as Well as in studying quiescence. The 
information gleaned from reactivation and quiescence stud 
ies Will be of bene?t in drug discovery. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-1. The neural cells can be prepared as described herein 
and introducing a reactivator can be accomplished according 
by any means Which causes reactivation. 
Also provided are methods for determining the ability of 
a test reagent to suppress virus reactivation from a 
quiescently-infected neural cell, comprising introducing a 
test reagent to a quiescently-infected neural cell described 
herein; and introducing to said neural cell a reactivator; and 
determining if reactivation has been suppressed. 
This aspect of the invention is particularly useful for 
identifying potential anti-viral drugs. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-1. The neural cells can be prepared as described herein, 
introducing a reactivator can be accomplished by any means 
Which causes reactivation, and determining reactivation can 
be accomplished by any means, including, for example, 
those means described in the examples, or other Well-known 
means. 
Also provided are methods for determining the ability of 
a test reagent to induce virus reactivation from a neural cell, 
comprising introducing a test reagent to a quiescently 
infected neural cell described herein; and determining if 
reactivation has been induced. 
This aspect of the invention is particularly useful for 
identifying potential reactivators. In one aspect, this embodi 
ment is useful in drug discovery as part of a toxicology 
screen. For example, if a reagent such as a drug (or potential 
drug), vaccine, carrier, food, or environmental condition is 
implicated through the use of this method as a reactivator of 
quiescent virus, it Would be advisable for an infected indi 
vidual to avoid the reagent, since reactivation of virus is 
normally a detrimental to the individual. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-1. The neural cells can be prepared as described herein, 
introducing a test compound can be accomplished by any 
means Which causes interaction betWeen the test compound 
and the neural cells, and determining reactivation can be 
accomplished by any means, including, for example, those 
means described in the examples, or other Well-known 
means. 
Also provided are methods for eliciting phenotypic 
change in a neural cell, introducing a reactivator to a 
quiescently-infected neural cell described herein, and elic 
iting a phenotypic change in said neural cell. Preferred are 
such methods Wherein said phenotypic change is selected 
from the group consisting of synthesis of myelin, synthesis 
of neurotransmitter, degradation of neurotransmitters, cell 
death, and viral shedding. 
This aspect of the invention is particularly useful in 
studying disease states, such as multiple sclerosis, or other 
neuron-associated diseases. The neural cells can be directed 
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via molecular techniques, for example, to result in disease 
state upon activation. Alternatively, the neural cells can be 
directed to be positive in?uences on the environment, such 
that gene therapy studies Will be possible using this embodi 
ment. In all aspects of the present embodiment, the methods 
Will be useful for drug discovery in that the mechanisms of 
phenotypic change can be studied. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-1. 
Also provided are methods for determining the suscepti 
bility of a person infected With a quiescent virus to reacti 
vation by a reagent, comprising introducing a reactivator to 
a quiescently-infected neural cell described herein, Wherein 
the neurotropic virus is a strain isolated from a person 
infected With said neurotropic virus; and determining the 
relative magnitude of phenotypic or genomic reactivation. 
This aspect of the present invention is particularly useful 
for patient diagnosis and directed medical care. Since some 
strains are more reactivatable than others, it is important to 
determine the aggressiveness and/or timing of treatment. 
The present embodiment, for example, can identify those 
individuals Who harbor a strain particularly reactivatable by 
sunlight, in Which those patients could use sunscreen or 
avoid the sun. The method Would provide information to 
patients Who have a less reactivatable strain, so that sup 
pressor drug levels can be loWered in comparison to those 
Who have a highly reactivatable strain. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-1. 
Also provided are methods to determine the ability of a 
non-neurotropic virus to become quiescent and/or reactivat 
able in a neural cell line, comprising introducing a non 
neurotropic virus to differentiated and viable PC12 cells in 
a serum-free medium, said differentiated PC12 cells being in 
a container; and incubating said container With an antiviral 
reagent for a time necessary to accomplish quiescence of 
viral activity; and removing said antiviral agent from said 
container; and determining said non-neurotropic virus’s 
ability to become quiescent and or reactivatable. 
This aspect of the present invention is particularly useful 
to identify additional viruses Which may be amenable to the 
present invention. The preferred quiescently-infected neural 
cells for use in this embodiment are those comprising 
neurotropic herpes viruses, preferably HSV-1. 
Also provided are methods to identify nucleic acid mol 
ecules and/or proteins involved in virus reactivation, com 
prising reactivating a quiescently-infected neural cell 
described herein With a reactivator; and identifying nucleic 
acid molecules and/or proteins Which are uniquely expressed 
during reactivation. 
This aspect of the present invention is particularly useful 
for general scienti?c research or to study possible targets for 
drug discovery. The preferred quiescently-infected neural 
cells for use in this embodiment are those comprising 
neurotropic herpes viruses, preferably HSV-1. 
Also provided are methods to identify the origins of DNA 
replication important to virus reactivation, comprising reac 
tivating a quiescently-infected neural cell described herein 
With a reactivator; and identifying the origins of replication 
Which are uniquely associated With reactivation. 
This aspect of the present invention is particularly useful 
for general scienti?c research or to study possible targets for 
drug discovery. The preferred quiescently-infected neural 
cells for use in this embodiment are those comprising 
neurotropic herpes viruses, preferably HSV-1. 
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Also provided are methods to determine a reagent’s 
ability to inhibit establishment of a viral infection, compris 
ing introducing a non-neurotropic virus to differentiated and 
viable PC12 cells in a serum-free, test reagent-containing 
medium, said differentiated PC12 cells being in a container; 
and incubating said container With an antiviral reagent for a 
time necessary to accomplish quiescence of viral activity in 
the absence of said test reagent; and removing said antiviral 
agent from said container; and determining said test 
reagent’s ability to inhibit quiescence. 
This aspect of the invention is particularly useful for 
identifying reagents Which could be used as an anti-viral 
drug. The reagents identi?ed as inhibiting the establishment 
of quiescence Would be particularly effective to administer 
during the ?rst lytic phase of a viral infection. The preferred 
neural cells for use in this embodiment are those Which are 
neurotropic herpes viruses, speci?cally HSV-1. 
Also provided are methods to screen an attenuated virus’ 
relative ability to be reactivated, comprising introducing a 
reactivator to a quiescently-infected neural cell described 
herein, Wherein the neurotropic virus is an attenuated virus; 
and determining the relative magnitude of reactivation. 
This aspect of the invention is particularly useful to 
determine the reactivatability of potential or actual vaccines. 
Vaccines Which can reactivate, Whether alone, or in combi 
nation With an additional reagent, Would be potentially 
dangerous. In other Words, this aspect of the invention can 
be used a specially-designed toxicology assay. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-1. 
EXAMPLES 
Example 1 
Media, Cell Lines and Virus 
Rat pheochromocytoma (PC12) and Vero (African green 
monkey kidney) cells Were obtained from ATCC (Rockville, 
Md.). All culture media and supplements Were purchased 
from Gibco BRL (Gaithersburg, Md.) unless otherWise 
indicated. PC12 cells Were groWn in RPMI 1640 media 
containing 5% fetal bovine serum (FBS) and 10% heat 
inactivated horse serum Vero cells Were groWn and 
maintained in M199 medium containing 5% FBS. Cells 
Were incubated at 37° C. in a humidi?ed incubator With 5% 
CO2. All media Was supplemented With penicillin (100 
units/ml) and streptomycin (100 mg/ml). HSV-1 KOS (M) 
Was a kind gift of R. Thompson (University of Cincinnati, 
Cincinnati, Ohio). HSV-1 strain 17 Was a kind gift of N. 
Fraser (Wistar Institute, Philadelphia, Pa.). Viral stocks Were 
prepared in Vero cells and maintained at —85° C. Virus 
production Was determined using supernatants from infected 
cultures in a direct plaque assay (DPA) on monolayers of 
Vero cells as previously described (Miller and Smith, 1991). 
Example 2 
Morphologic Differentiation 
PC12 cells Were collected from ?asks, dissociated by 
passage through a 22-gauge needle and plated on 6-or 
12-Well tissue culture dishes (Becton Dickinson LabWare, 
Franklin Lakes, N.J.) coated With rat tail collagen type 1 
(Becton Dickinson), unless otherWise indicated. Collagen 
Was applied as recommended by the supplier. Morphologic 
differentiation Was initiated With 50 ng/ml of 2.5 S mouse 
nerve groWth factor (NGF) (Becton Dickinson) in 
RPMI1640 media containing 5% FBS and 10% HS or RPMI 
containing 0.1% bovine serum albumin, fraction V (BSA) as 
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described by Green and Tischler (1976), Green (1978) and 
Gunning et al (1981). Morphologic differentiation Was con 
?rmed by microscopic visualization of dendritic processes. 
Media Was changed every 2—3 days. 
Example 3 
Establishment of a Quiescent and Persistent Infection 
Neurally-differentiated PC12 cells (Nd-PC12) Were 
infected With virus, in a volume of 0.4 or 1.0 ml/Well, for 12 
and 6-Well plates, respectively, Without agitation at the 
indicated multiplicity of infection (MOI) overnight at 37° C. 
Acycloguanosine (ACV), purchased from Sigma (St. Louis, 
Mo.) Was added to the medium, at the indicated 
concentrations, from days —1 to the indicated time post 
infection (p.i.). After ACV WithdraWal, a quiescent state 
(i.e., free of detectable infectious virus in culture superna 
tants and lysates) Was maintained for at least 7 days prior to 
induction. 
Example 4 
Reactivation Stimuli 
HSV-1 quiescently infected PC12 cells (QIF-PC12),that 
Were free of detectable infectious virus, Were subjected to 
RPMI media containing BSA and NGF supplemented With 
50 mM forskolin (Sigma) for 2 days at the indicated times. 
Forskolin Was prepared in DMSO (Sigma) as recommended 
by Huang et al (1982). 
Example 5 
RNA Isolation and cDNA Synthesis 
Cells Were harvested for RNA isolation from duplicate 
Wells on the days indicated by scraping cell sheets in PBS 
folloWed by centrifugation at 2,000 rpm for 5 min. Cell 
pellets Were Washed With PBS, pelleted as above and stored 
at —85° C. folloWing removal of PBS. RNA Was isolated 
using the Qiagen RNeasy Total RNA Kit as recommended 
by the manufacturer. 3 mg of each RNA sample Was treated 
With DNAse I (Boehringer Mannheim, Indianapolis, Ind.) in 
20 mM Tris-HCl (pH 8.4), 2 mMMgCl2, 50 mM KCl, and 
10 Units of RNase-free DNase I in a ?nal volume of 20 ml 
at room temperature for 15 minutes. DNase I Was inactivated 
by adding 2 ml EDTA (25 mM, pH 8.0) and heating at 65° 
C. for 10 min. cDNA Was generated With SuperScript II 
reverse transcriptase (Gibco BRL) and random primers 
(Gibco BRL) as recommended by the supplier. cDNA Was 
stored at —20° C. until use. 
Example 6 
RT-PCR 
PCR reactions containing 20 mM Tris-HCl (pH 8.4), 50 
mM KCl, 1.5mM MgC12, 0.2 mM each dNTP, 0.5 mM of 
each primer, 2.5 units Taq DNA polymerase (Gibco BRL) 
and cDNA derived from 1,500 cells Were prepared on ice. 
Samples Were denatured at 94° C. for 3 minutes folloWed by 
35 cycles (94° C. for 45 seconds, 550 C. for 30 seconds, 72° 
C. for 90 seconds), for HSV target sequences, and 26 cycles, 
for the host target. Controls containing 10-fold dilutions of 
HSV-1 DNA ranging from 1.25 fg to 12.5 pg (7.5 to 75,000 
genome equivalents) or 2-fold dilutions of PC12 cellular 
DNA ranging from 0.5 ng to 4.0 ng (155 to 1240 haploid 
genome equivalents) Were performed in parallel to assess the 
levels of cDNA in each sample. Experimental and control 
samples Were performed in duplicate and triplicate, respec 
tively. The speci?city of viral speci?c PCR products Were 
veri?ed by Southern blot analysis as described by BroWn 
(1993). In brief, equivalent amounts of PCR products Were 
applied to 2.0% agarose gels and electrophoresed in 0.5>< 
TBE at 50V for 45—60 min. DNA Was transferred to Magna 
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NT nylon membranes (Micron Separation Inc., Westboro, 
Mass.) by capillary action folloWing denaturation and neu 
traliZation. Membranes Were hybridiZed to digoxigenin 
labeled (DIG Oligonucleotides 3‘ end labeling and DIG 
Luminescent Detection Kits [Boehringer Mannheim]) 
probes speci?cfor HSV-1 gene sequences. The blots Were 
scanned using the Phosphorimager (Molecular Dynamics, 
Sunnyvale, Calif.) and analyZed With GPTools softWare 
(Biophotonics, Ann Arbor, Mich.). Levels of the host 
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) mes 
sage Were determined for each sample to monitor the reverse 
transcriptase reaction. 
Example 7 
Conditions for Maintenance of Long Term, Non-dividing 
Differentiated PC12 Cultures 
Previous studies have demonstrated NGF-differentiated 
PC12 (Nd-PC12) cells can be maintained as non-dividing 
cultures both in the presence and absence of serum (Greene, 
1978; Greene and Tischler, 1976).These cultures have been 
studied on non-coated (Block et al, 1994) and collagen 
coated dishes (Greene and Tischler, 1976). Preliminary 
studies in our laboratory, hoWever, indicated that a signi? 
cant portion of PC12 cells cultured in the presence of serum 
continued to divide and is consistent With the ?ndings of 
others (Goodman et al, 1979; Ignatius et al, 1985). Because 
a differentiated, non-dividing and adherent cell population 
Was desired, We ?rst determined Whether continued groWth 
of cells Was the result of high plating density that may have 
exhausted the NGF supplied (Gunning et al, 1981). To make 
this determination, cells Were plated at tWo different densi 
ties on collagen and non-collagen coated dishes. Cells plated 
at loW density Were NGF differentiated in the presence of 
serum (+serum) Whereas those plated at high density Were 
differentiated in the absence of serum (—serum). In collagen 
coated Wells containing media supplemented With serum, 
the cell density increased more than 30-fold (i.e., from 
5.5><103 to 1.9><105 cells/Well) by 17 days post-plating(p.p.) 
With an additional 12-fold increase (to 2.4><10° cells/Well) in 
the folloWing 32 days. The cell density of parallel cultures 
groWn on non-coated plates also continued to divide main 
taining cell densities of about 50% of those cultured on 
collagen-coated dishes. When Nd-PC12 cells Were groWn on 
coated dishes in the absence of serum (—serum) a relatively 
constant cell number Was maintained for 7 Weeks With a 
subsequent loss of about 50% of the cells during the fol 
loWing 18 days. Parallel cultures maintained in serum free 
conditions did not adhere Well to non-coated dishes. The 
addition of serum to minus-serum Nd-PC12 cultures on day 
25 pp. resulted in a 70% increase in cell number Within 6 
days and an additional 14-fold increase in the folloWing 18 
days achieving equivalent cell densities as +serum cultures. 
These data demonstrate that a relatively constant number of 
Nd-PC12 cells could be maintained as non-dividing cultures 
only When cultured in the absence of serum and that cell 
groWth arrest is reversible upon the addition of serum to the 
media for up to 25 days p.p. 
Example 8 
Reactivation from Long-term (50 Days) HSV-1 Infected, 
Quiescent PC12 Cultures With Forskolin 
To determine Whether Nd-PC12 cells could harbor HSV-1 
in a recoverable state for long periods of time folloWing 
removal of ACV, Nd-PC12 cultures Were infected With strain 
KOS (M) at a MOI of 27+3 on day 15 pp. and maintained 
as quiescently infected cultures (QIF-PC12) as described in 
FIG. 3. Under these conditions, all cultures Were free of 
detectable levels of infectious virus in the supernatants at the 
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time of ACV WithdraWal. Virus Was detected in only 1 of 35 
cultures during the following 8 days, and virus Was not 
detected from total cell lysates of our infected control Wells 
on day 16 post-ACV WithdraWal. To determine if NGF 
WithdraWal Would induce virus production, as described by 
Wilcox and Johnson (1987), NGF Was WithdraWn on day 8 
post-ACV WithdraWal. Virus Was detected by day 8 post 
treatment in 100% of forskolin-induced control cultures, 8% 
NGF-free cultures, and 5% of infected untreated control 
cultures. Except for the detection of virus in 2 of the 
remaining 14 infected untreated control Wells on day 17 
post-ACV WithdraWal, virus Was not detected in infected 
control Wells for the remaining 39 days. 
To determine Whether these virus negative (non 
producing) cultures Were still capable of producing virus, 4 
of 12 cultures Were treated With forskolin on day 38, and 4 
of 8 Were treated With forskolin on day 49 post-ACV 
WithdraWal. Induction With forskolin at these later dates 
resulted in the detection of virus in 75 % and 50% of cultures, 
respectively, compared With 0% in the remaining infected 
untreated control cultures. These data indicate that virus can 
be recovered from long-term QIF-PC12 cultures When 
induced With forskolin. 
Example 9 
Detection of Viral Transcripts During the Establishment and 
Maintenance of the Quiescent Phase of QIF-PC12 Cultures 
To study viral gene expression during the establishment 
and maintenance phases of a quiescent infection, QIF-PC12 
cells Were established under conditions that minimiZe the 
effects of high copy number of viral genomes. This Was 
achieved using strain 17 because it reactivates more ef? 
ciently in this model than KOS. The infections Were per 
formed at an MOI of 0.5. The rate of virus reactivation from 
QIF-PC12 cells established under these conditions are pre 
sented in a subsequent manuscript (Danaher et al, 1999 J 
Neuro Virol). RNAs from duplicate QIF-PC12 cell cultures 
Were collected at the indicated time points throughout the 31 
day period and analyZed by RT-PCR in duplicate. The 
speci?city of the RT-PCR products Were con?rmed by 
Southern blot analysis. FIG. 4 shoWs representative results 
from one of 4 samples from each time point examining the 
viral and host genes (G3PDH gene). Aprecipitous decline in 
transcripts occurred from the selected representatives of the 
3 classes of the herpes virus genes (i.e., immediate-early [0t], 
early [[3], late tested folloWing day 1 pi. Detection of 
transcripts from a genes extended to as long as 10 days after 
drug removal (i.e., 20 days p.i.), as typi?ed by the (x27 
product. Transcripts from the UL30 (DNA polymerase 
gene), representing the [3 genes, became undetectable by the 
day of ACV WithdraWal (i.e., day 10 pi). Gamma genes, as 
represented by UL18 (VP23), Were at, or beloW the level of 
detection by day 20 pi In contrast to the precipitous decline 
in all classes of viral gene transcripts represented, the stable 
LAT transcript persisted, although someWhat reduced com 
pared to day 1 pi. levels, for the length of the assay. 
From FIG. 4, it is apparent that the products of the 
representative viral genes, except for LAT, diminished sig 
ni?cantly throughout the 31 day period assayed. Expression 
of the host cell gene G3PDH Was constant throughout the 
time period measured. Table 2 shoWs the values obtained 
from duplicate Southern analysis from duplicate cultures at 
each time point of viral RT-PCR products quanti?ed by 
densitometry during the 31-day period. The sensitivity in all 
cases Was greater than 0.1 target sequences per cell, With a 
range of 0.010 to 0.078 represented by VP23 and (X4, 
respectively. Consistent With the results shoWn in FIG. 4, a 
precipitous decline in viral transcripts associated With pro 
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ductive infection Was determined folloWing day 1 p.i., 
Whereas levels of LAT remained relatively constant. Tran 
script production from the (x0 and UL30 (DNA polymerase 
gene) declined the fastest during the ?rst ?ve days p.i. By 
day 10 pi. (day of ACV WithdraWal), the level of UL18 
(VP23) and a gene expression Was doWn 93—99%, and the 
level of UL30 expression fell beloW the level of detection. 
FolloWing the WithdraWal of ACV, the expression of these 
genes continued to decline and by day 20 the average cDNA 
copies for the ot genes Were beloW the level of detection. By 
day 20 and thereafter, the average cDNA copies for UL18 
Were at the level of detection and beloW. In contrast, LAT 
transcripts Were reduced 53% by day 10 pi. but remained 
relatively constant thereafter, and never dropped near, or 
beloW, the level of detection in the assay. Host G3PDH RNA 
levels remained relatively constant throughout the assay 
period. 
Example 10 
Viral Speci?c Product Was not Detected in Uninfected 
Control Cultures or in Minus Reverse-transcriptase Controls 
To strengthen the belief that the above analysis Was 
undertaken on cells that Were truly quiescent for HSV-1 
genomes, parallel 12-Well cultures,that Were determined to 
be non-productive, Were treated With forskolin on day 20 pi. 
and reactivated With similar kinetics to that of KOS, as 
reported in the previous section, With 75% reactivation by 7 
day post-forskolin treatment. This experiment Was done 
under similar conditions described in FIG. 2. 
Example 11 
Asynchronous and Spontaneous Release of HSV-1 from 
PC-12 Cells 
The lack of an adequate cell culture model for latency of 
herpes simplex virus type 1 (HSV-1) contributes to our poor 
understanding of HSV-1 reactivation. The objective of this 
research Was to establish a latent cell culture model that 
supports HSV-1 in a state suitable for reactivation studies. 
Rat pheochromocytoma (PC-12) cells Were groWn in media 
containing 50 ng/mL nerve groWth factor. Thirty-six indi 
vidual cultures in 12-Well plates Were infected With HSV-1 
(strain KOS) at a MOI of 20 in the presence of 50 mM 
acycloguanosine (ACY). After 10 days, ACY Was removed 
(Day 0) and the level of virus replication Was determined by 
direct plaque assay (DPA) on monolayers of monkey kidney 
(Vero) cells for up to 60 days. Results of the DPA shoWed 
that virus Was spontaneously and asynchronously released 
from four different culture Wells on days 8, 10, 17 and 32. 
Overall, the rate of virus shedding Was 6 of 445 assays 
(1.3%). In comparison With ACY treated cultures, 100% of 
untreated cultures produced virus continuously until total 
cytopathic effect Was achieved (mean 22 days) (p<0.001; 
Chi square). These data demonstrate that the majority of 
cells do not release virus, and the loW rate of viral shedding 
from PC-12 cells is similar to the loW rate of shedding that 
occurs in humans (Kameyama et al.,1988). This Work pro 
vides preliminary evidence that HSV-1 can be harbored in a 
potentially latent state in cell culture, and that these cells 
may serve as a good model for studies of HSV-1 reactiva 
tion. 
Example 12 
HSV-1 Release from PC-12 Cells Induced by Heat Stress 
Rat pheochromocytoma PC-12 cells Were groWn under 
conditions that result in non-dividing neuronally differenti 
ated cells, infected With HSV-1 (17+) at a MOI of <10, and 
maintained in acyclovir (ACV) for 10 days as described. 
Eight days after ACV removal, cells Were subjected to heat 
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(39° C. to 43° C.) for 1 to 3 hrs, or 50 pm forskolin (positive 
control). The presence of virus on day 0—25 post-infection 
Was determined using supernatants from infected cultures in 
a direct plaque assay (dpa). 
Treatment Positive Cultures Positive Cultures 5d Positive Cultures 7d 
(Tx) post-Tx post-Tx post-Tx 
39° c. 0/12 (0%) 0/12 (0%) 0/12 (0%) 
41° c. 1/12 (8%) 1/12 (8%) 1/12 (8%) 
43° c. 12/12 (100%) 12/12 (100%) 12/12 (100%) 
Forskolin 0/12 (0%) 11/12 (92%) 12/12 (100%) 
DMSO 0/12 (0%) 0/12 (0%) 0/12 (0%) 
Negative 0/24 (0%) 0/24 (0%) 0/24 (0%) 
control 
Virus Was released more efficiently from cells subjected to 
43° C. and forskolin compared With cells subjected to loWer 
temperatures, Whereas no virus Was released from cells 
exposed to fresh media +/— DMSO (p<0.001; ANOVA). 
Consistent With our previous Work, forskolin induced rep 
lication by day 5, hoWever heat stress induced replication in 
100% of cultures by day 2. These data shoW that virus 
replication can be ef?ciently, predictably and rapidly 
induced from a state of nonproductivity by heat shock, and 
that this system may serve as a cell culture model for the 
study of HSV-1 latency and reactivation. 
Example 13 
Effect of Hormones on HSV-1 Release from Nonpermissive 
PC-12 Cells 
This study Was conducted to identify biochemicals that 
could predictably release virus from this neuronal cell 
model. Individual PC-12 cultures groWn, neuronally differ 
entiated in 12-Well plates, infected With HSV-1 (strain 17+) 
at a MOI of <10 and maintained in acyclovir (ACV) for 10 
days. Eight days after ACV removal, cells Were subjected to 
dexamethasone (20, 5, 1, 0.2 MM), epinephrine (100, 50, 10, 
1 pM), estrogen (10, 2, 0.5, 0.1 nM), forskolin (50 21M) or 
control media. Supernatants from cultures Were removed 
daily beginning day 10 post infection and the presence of 
virus Was determined by direct plaque assay (dpa) for 18 
days post-treatment An average of <25 plaques per 
positive culture Was rated light, an average of 26 to 75 
plaques perpositive culture Was rated moderate, and an 
average of >75 plaques per positive culture Was rated heavy. 
Results shoWed that forskolin and estrogen caused signi? 
cantly more virus replication than the other treatments 
(p<0.05, Chi square). Virus replication occurred in 8.0% of 
control cultures (days 2—16 pTx), 10.5% of dexamethasone 
treated cultures (days 3—7 pTx), 15.3% of epinephrine 
treated cultures (days 4—7 pTx), 28.6% of estrogen-treated 
cultures (days 5—18 pTx) and 74.3% of forskolin-treated 
cultures (days 4—7 pTx). The magnitude of viral release Was 
heavy in cultures treated With forskolin and epinephrine, 
moderate With estrogen, and light With dexamethasone. 
Optimum viral shedding occurred When cells Were treated 
With forskolin (50 pm), estrogen (2 nm), epinephrine (10 
pm) and dexamethasone (1 pm). These data demonstrate that 
estrogen and forskolin trigger virus replication from non 
permissive PC12 cells that harbor HSV-1, and that these 
agents may be useful for study of events that regulate HSV 
reactivation. 
Example 14 
Strain Speci?city for HSV-1 Replication in PC12 Cells 
The aim of this study Was to determine Whether our cell 
culture model for HSV-1 latency displayed strain speci?city. 
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Rat pheochromocytoma PC12 cells Were groWn under con 
ditions that result in non-dividing neuronally differentiated 
cells. Cells Were infected With HSV-1 (strains KOS, 17+, 
McKrae, and 2903 [a McKrae LAT-de?cient mutant]) at 
MOIs 0.5 to 20, and maintained in acycloguanosine (ACV) 
for 8 days as described. Virus replication Was detected using 
supernatants from infected cultures in a direct plaque assay 
(dpa) using monkey kidney (Vero) cells. During the Week 
folloWing ACV removal, HSV-1 Was detected in 88 and 96% 
of cultures infected With McKrae (MOI=4 and 20, 
respectively), 38 and 71% of cultures infected With 17+ 
(MOI=0.5 and 2.5, respectively), 4 and 12% of cultures 
infected With KOS (MOI=1 and 5.6, respectively), and 0% 
of cultures infected With 2903 (MOI=2 and 10). These data 
indicated that tWo of the strains (KOS, 2903) Were suitable 
for reactivation studies. To induce replication in non 
productive cells, KOS-and 2903-infected cultures Were sub 
jected to forskolin (50 mm) 20 days post infection. 
Positive Cultures 7d Positive Cultures 7d 
After Mock- After Forskolin 
Strain MOI Treatment Treatment 
KOS 1.1 0/11 (0%) 7/12 (58%) 
KOS 5.6 1/12 (8%) 7/9 (78%) 
2903 2 0/12 (0%) 2/12 (17%) 
2903 10 0/12 (0%) 2/12 (17%) 
Data in the table shoWs that a signi?cantly greater per 
centage of cultures produced virus When subjected to for 
skolin compared With mock-treated cultures (p<0.01, Chi 
square), and a relationship betWeen MOI and inducible 
replication in KOS-infected cultures existed. These data 
suggest that there is strain speci?city for establishment of a 
“latent state” and for inducible-replication in PC12 cells, 
and that a high viral-to-cell inoculum ratio may provide a 
viral advantage for entering latency. Also, the deletion of 
LAT sequences may inhibit the virus’ ability to replicate in 
neuronally differentiated PC12 cells. 
Example 15 
Serotype Speci?city for HSV Replication in PC12 Cells 
The aim of this study Was to determine Whether HSV 
replication displayed serotype speci?city in neurally 
differentiated, rat pheochromocytoma PC12 cells. Cells 
Were groWn under conditions that result in non-dividing 
neuronally differentiated cells as described, and infected 
With HSV-1 or HSV-2 at MOI<1.0 in the presence (HSV-1 
strain 17+; HSV-2 strains 333, G) or absence of ACV 
(HSV-1 strains 17+, McKrae, KOS, 2903, 2903r). Antiviral 
therapy Was continued for 8 days. Virus replication Was 
detected using supernatants from infected cultures in a direct 
plaque assay (dpa) using monkey kidney (Vero) cells. In the 
absence of ACV, all HSV-1 strains replicated in PC12 cells, 
hoWever HSV-2 (G) did not groW. In the presence of ACV, 
a nonproductive state Was established. In an attempt to 
induce replication in non-productive cells, cultures Were 
subjected to forskolin (50 mM) or heat stress (43° C., 3 hrs) 
19 days and 26 days post infection [pi], respectively. HSV-1 
(17+) Was shed from 12/12 cultures 4 days after forskolin 
treatment and 32/33 cultures 2 days after heat stress com 
pared With 2/22 control cultures (p<0.01, Chi square). 
HSV-2 (333) Was minimally shed from 4/46 cultures 2 days 
after heat stress, 1/24 cultures after forskolin treatment and 
0/23 control cultures. HSV-2 (G) Was shed from 1/24 
cultures 2 days after heat stress, 0/ 12 cultures after forskolin 
treatment and 0/12 control cultures. These data suggest that 
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there is serotype speci?city for HSV replication, and 
inducible-replication, in PC12 cells, and that ACV affects 
this susceptibility. 
We claim: 
1. APC12 cell quiescently infected With a human herpes 
simpleX 1 virus. 
2. A method of reactivating a quiescent virus from at least 
one quiescently-infected PC12 cell, comprising: introducing 
a reactivator to a cell of claim 1. 
3. A method for determining the ability of a test reagent 
to suppress virus reactivation from a quiescently-infected 
PC12 cell of claim 1, comprising: 
introducing a test reagent to said PC12 cell; and 
introducing to said PC12 cell a reactivator; and 
determining if reactivation has been suppressed. 
4. A method for determining the ability of a test reagent 
to induce virus reactivation from a PC12 cell of claim 1, 
comprising: 
introducing a test reagent to said PC12 cell; and 
determining if reactivation has been induced. 
5. Amethod for eliciting phenotypic change in a PC12 cell 
of claim 1, 
introducing a reactivator to said PC12 cell, and 
eliciting a phenotypic change in said PC12 cell. 
6. The method of claim 5 Wherein said phenotypic change 
is selected from the group consisting of synthesis of myelin, 
synthesis of neurotransmitter, cell death, and viral shedding. 
7. A method for determining the susceptibility of a person 
infected With a quiescent virus to reactivation by a reagent, 
comprising: 
introducing a reactivator to a PC12 cell of claim 1, 
Wherein the neurotropic virus is a strain isolated from 
a person infected With said neurotropic virus; and 
determining the relative magnitude of phenotypic or 
genomic reactivation. 
8. A method to identify nucleic acid molecules and/or 
proteins involved in virus reactivation, comprising: 
reactivating a PC12 cell of claim 1 With a reactivator; and 
identifying nucleic acid molecules and/or proteins Which 
are uniquely expressed during reactivation. 
9. A method to identify the origins of DNA replication 
important to virus reactivation, comprising: 
reactivating a PC12 cell of claim 1 With a reactivator; and 
identifying the origins of replication Which are uniquely 
associated With reactivation. 
10. Amethod to screen an altered virus’ relative ability to 
be reactivated, comprising: 
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introducing a reactivator to a PC12 cell of claim 1, 
Wherein the neurotropic virus is an attenuated neuro 
tropic virus; and 
determining the relative magnitude of reactivation. 
11. A method of establishing quiescently-infected PC12 
cells, comprising: 
introducing a human herpes simpleX 1 virus to neurally 
differentiated and viable PC12 cells in a serum-free 
medium, said differentiated PC12 cells being in a 
container; and 
incubating said container With an antiviral reagent for a 
time necessary to accomplish quiescence of viral activ 
ity; and 
removing said antiviral agent from said container. 
12. The method of claim 11, Wherein the antiviral reagent 
is acyclovir. 
13. The method of claim 12, Wherein said container is 
incubated With acyclovir for approximately 5 to 12 days. 
14. The method of claim 13, Wherein said container is 
incubated at a temperature less than 40 degrees Celsius. 
15. The method of claim 12, Wherein said serum free 
medium alloWs for constant cell density and imparts neural 
characteristics to said cells. 
16. Amethod to determine the ability of a non-neurotropic 
virus to become quiescent and/or reactivatable in a PC12 
cell line, comprising: 
introducing a non-neurotropic virus to differentiated and 
viable PC12 cells in a serum-free medium, said differ 
entiated PC12 cells being in a container; and 
incubating said container With an antiviral reagent for a 
time necessary to accomplish quiescence of viral activ 
ity; and 
removing said antiviral agent from said container; and 
determining said non-neurotropic virus’ ability to become 
quiescent and/or reactivatable. 
17. A method to determine a reagent’s ability to inhibit 
establishment of a quiescent viral infection, comprising: 
introducing a virus to differentiated and viable PC12 cells 
in a serum-free, test reagent-containing medium, said 
differentiated PC12 cells being in a container; and 
incubating said container With an antiviral reagent for a 
time necessary to accomplish quiescence of viral activ 
ity in the absence of said test reagent; and 
removing said antiviral agent from said container; and 
determining said test reagent’s ability to inhibit quies 
cence. 
